N-gene Research Laboratories, Inc.

Cytrx Corporation

Péter Literáti Nagy

Gábor Balogh

László Vígh

Zoltán Szilvássy

László Ürögdi

Ede Márványos

Ibolya Horváth

Zsolt Török

Mária Kürthy

Attila Glatz

György Dormán

Beatrix Farkas

Andrea Jednákovits

Katalin Bíró

László Korányi

László Jaszlits

Mihály Barabás

Erzsébet Hegedüs

György Rabloczky

Éva Udvardy

András Rabloczky, Legal Representative

Bea Mézes

Eszter Kovács

Balázs Sümegi

Sándor Bernáth

Kálmán Tory

Jesse Roth

Dénes Medzihradszky

József Mandl

Jenö Szilbereky

Ernö Duda

Kálmán Takács

Jenó Szilbereky

Ernó Duda

Attila Kolonics

János Egri

László Vigh

Mike Brownstein

Zoltán Szilvassy

Sándor Bernath

Kálmán Takacs

The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.

Synergistic pharmaceutical combination for the prevention or treatment of diabetes

O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15) or a pharmaceutically suitable acid addition salt thereof can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight gain.

Prevention and treatment of obesity

A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof

Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof

Growing community of inventors

Budapest, Hungary

Péter Literáti Nagy